EW News and Press, Edwards Lifesciences Corporation From 06/03/19

IRVINE, Calif. , June 3, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received notice of an unsolicited "mini-tender offer" by ...

The World is Not Ending (even in 12 years) and Neither is the Stock Market Chief Strategist Joseph Zidle of Blackstone, I paraphrase: "The trade war will not pull the US or China into recession. A European recession will not bring us down either. The silver lining is that we will see an econ...

New six-month data from a study called CLASP evaluating Edwards Lifesciences' (NYSE: EW ) PASCAL transcatheter valve repair system in patients with clinically significant mitral valve regurgitation (MR) despite optimal medical treatment showed a treatment benefit. The results were prese...

PARIS , May 22, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced strategic clinical and regulatory milestones for its Edwards PASCAL transcatheter va...

IRVINE, Calif. , May 15, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Every Heartbeat Matters signature charitable initiative is on sch...

Introduction Edwards Lifesciences ( EW ) describes itself this way: ... we continue to lead the field of tissue replacement heart valves and repair products and advanced hemodynamic monitoring, which have helped treat and manage more than 2 million patients worldwide. EW was spun off...

The board of Edwards Lifesciences (NYSE: EW ) has authorized the repurchase of another $1B of its common stock. $1.3B remains under its existing buyback program. More news on: Edwards Lifesciences Corporation, Healthcare stocks news, Read more ...

TORONTO , May 7, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced results from the COMMENCE clinical study. The data show that Edwards' bioprostheti...

Introduction Those who read my previous articles, including my investment strategy statement , should be familiar with the investment approach that I have been sticking to - buying wonderful businesses at sensible prices. The core here is to evaluate the "wonderfulness," which points to fun...

Introduction Edwards Lifesciences ( EW ) is a leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The company is also an established player hemodynamic monitoring systems in the hospital setting. In the ...